A Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal Consta Following a Single Intramuscular Injection at 25 mg or 50 mg in Stable Patients With Schizophrenia and/or Schizoaffective Disorder
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2015
At a glance
- Drugs Risperidone (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Luye Pharma Group
- 17 Jun 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 03 Mar 2015 Planned End Date changed from 1 Nov 2014 to 1 May 2015 according to ClinicalTrials.gov record.
- 03 Mar 2015 Planned primary completion date changed from 1 Nov 2014 to 1 May 2015 according to ClinicalTrials.gov record.